Cargando…
Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
Grb7 has potential importance in the progression of cancer. We have previously identified a novel peptide that binds to the SH2 domain of Grb7 and inhibits its association with several different receptor tyrosine kinases. We have synthesised the Grb7 peptide, G7-18NATE, with two different cell penet...
Autores principales: | Pero, S C, Shukla, G S, Cookson, M M, Flemer, S, Krag, D N |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359946/ https://www.ncbi.nlm.nih.gov/pubmed/17426702 http://dx.doi.org/10.1038/sj.bjc.6603732 |
Ejemplares similares
-
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
por: De Lorenzo, C, et al.
Publicado: (2007) -
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
por: Meira, D D, et al.
Publicado: (2009) -
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007) -
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006) -
Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)